<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037465</url>
  </required_header>
  <id_info>
    <org_study_id>H-26547</org_study_id>
    <nct_id>NCT01037465</nct_id>
  </id_info>
  <brief_title>ROS Signaling in Endothelial Function</brief_title>
  <official_title>ROS Signaling in Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The vascular endothelium (inner lining of cells in blood vessels) normally prevents vasospasm
      and thrombosis by producing nitric oxide and other regulatory substances. In patients with
      atherosclerosis, endothelial function is impaired. Excess production of reactive oxygen
      species (free radicals) contribute to endothelial dysfunction in atherosclerosis, and some
      prior studies have shown a beneficial effect of antioxidant treatment on endothelial function
      in patients with coronary artery disease. On the other hand, reactive oxygen species may be
      required for normal endothelial function and antioxidant supplements failed to show a benefit
      in large clinical trials. The effect of antioxidant treatment on endothelial function in
      healthy subjects is unknown. The present study will test the hypothesis that scavenging
      reactive species might reduce endothelium-dependent vasodilation in healthy subjects.

      The study is a randomized, double-blind, placebo-controlled crossover study. Participants
      will receive 2.4 grams of oral NAC or similar-appearing placebo during the first visit, and
      then will cross over to the alternative treatment (NAC or placebo) for the second and final
      visit. We will examine endothelial function before and after treatment on each visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 26, 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial artery flow-mediated dilation</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood markers of antioxidant capacity</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sex: Male and Female subjects.

          2. Age range: 21-65 years old.

          3. Disease status: No acute, chronic, or debilitating medical condition or use of
             prescribed medications.

          4. Willingness and ability to provide written informed consent and the ability to
             understand, to participate and to comply with the study requirements.

        Exclusion Criteria:

          1. Women with a positive urine beta HCG pregnancy test and lactating women.

          2. Blood pressure greater than 140/90 mmHg; serum LDL cholesterol greater than 160 mg/dl;
             fasting blood sugar greater than 110 mg/dl.

          3. History of any cigarette smoking within one year of the study.

          4. Clinical history of any acute, chronic, or debilitating medical condition, including
             liver disease and peptic ulcer disease.

          5. Treatment with an investigational new drug within the last 30 days.

          6. History of a psychological illness or condition such as to interfere with the
             subject's ability to understand the requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Hamburg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2009</study_first_submitted>
  <study_first_submitted_qc>December 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Naomi M Hamburg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>endothelium</keyword>
  <keyword>cell signaling</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>reactive oxygen species</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

